Thoughts
Thought Leadership Posts
A Tell-All on Telehealth: Where Is Congress Heading Next?
By Billy Wynne and Josh LaRosa
|
May 16, 2019

The Centers for Medicare and Medicaid Services (CMS) recently enacted modest but important expansions in Medicare’s telehealth policy.
Telehealth, which uses telecommunications to support virtual health care delivery to improve access to and quality of health care, is moving from promise to reality. The benefits are appealing: Patients can interact with their providers remotely, which improves access to care and can help providers manage chronic conditions from afar....
+ Read More
Medicare Direct, A Blueprint For Public Option Waivers, Part 1: Introduction, Administration, And Financing
By Billy Wynne
|
June 17, 2019

There is a reason that Medicare for All has captured the enthusiastic support of a large majority of the public: The status quo for our health care system is unsustainable economically and unforgiveable morally. An honest assessment of the probability of Congress enacting Medicare for All–related legislation, however, demonstrates it is highly unlikely in the foreseeable future. ...
+ Read More
Medicare Direct, A Blueprint For Public Option Waivers, Part 2: Benefit Design, Provider Networks, And Reimbursement
By Billy Wynne
|
June 19, 2019

In all of the discussion and debate regarding Medicare for All and public option proposals, three essential considerations often get short shrift: the benefits enrollees will receive, the network of providers they will have access to; and the rates providers will be paid for delivering these services. These elements, however, really are the guts of any meaningful initiative of this scope. ...
+ Read More
Medicare Direct, A Blueprint For Public Option Waivers, Part 3: Waiver Design, Legal Authority, And Conclusion
By Billy Wynne
|
June 21, 2019

Perhaps the greatest weakness of the Medicare for All, Medicare for More, and public option proposals issued thus far is the fact that they require Congress to pass new legislation. That is certainly true for Medicare for All, it’s true for a Medicare buy-in, and it’s likely true for federally run public options. The biggest strength of Medicare Direct, by contrast, is that it requires no such action. ...
+ Read More
These Four Federal Proposals Would Have Major Health Implications for Immigrants
By Billy Wynne and Dawn Joyce
|
July 11, 2019

The Trump administration is seeking to modify federal regulations with harmful changes that could dramatically affect immigrants’ access to health care and other public benefits and weaken the health and social safety net. These policies affect access to health coverage, food assistance, housing, protections against discrimination, and more. These proposed changes could have major consequences for the health and well-being of immigrants across the country and especially in California, which has more immigrants than any other state....
+ Read More
The Drug Pricing Debate Part II: The Many Acts of Congress
By Billy Wynne, Josh Larossa, and Alyssa Llamas
|
July 30, 2019

As we outlined earlier this spring, congressional action on drug pricing continues to intensify. Key committees have advanced an array of reforms, demonstrating Congress’ intent to finalize legislation this year. We aim to clarify what that might include....
+ Read More
Public Option 1.0: Washington State Takes An Important Step Forward
By Billy Wynne
|
May 1, 2019

On Sunday, the Washington State legislature passed a bill to create standardized health plans in the state’s Exchange and establish new public option-ish plans that contract directly with its Health Care Authority, which operates the state’s Medicaid program. The hallmark of these new plans, and the foundation of their claim to the title “public,” is they are required cap provider reimbursements at Medicare-based levels....
+ Read More
The Drug Pricing Debate: Sizing Up Recent Actions and What May Come Next
By Billy Wynne and Josh LaRosa
|
March 7, 2019

What goes up must — or rather, should — come down.
Such is the thinking of the Trump administration when it comes to prescription drug pricing, at least. Over the past five years, 12 of the 20 most commonly prescribed brand-name drugs have seen price increases of more than 50 percent.
To date, most of what we’ve seen from the federal government is messaging and some initial proposals, with the majority coming from the administration. Congress, for its part, has initiated a series of drug pricing hearings and begun introducing meaningful legislation. The result is a wide array of policy alternatives, some of which stand a chance of being enacted....
+ Read More
Medicare For All Can Begin In 2021: Here’s How
By Billy Wynne and Alyssa Llamas
|
February 28, 2019

While Democratic presidential candidates and the newspaper headlines hash out the ideological nuances of a Medicare-based single payer coverage scheme, work is underway to consider how coverage can be expanded to those in need within a realistic timeframe at minimal cost or disruption to the existing system....
+ Read More
What to Expect in Health Policy Under a Divided Congress
By Billy Wynne and Dawn Joyce
|
January 8, 2019

The 2018 midterm elections were powered by a “blue wave” that flipped control of the House of Representatives from the GOP to the Democrats but left the Senate in Republican hands, meaning the two chambers of Congress will be divided at least until 2020. In the Senate, Republicans have a 53 to 47 majority and will continue to be led by Senator Mitch McConnell of Kentucky, while House Democrats gained a 235 to 199 majority....
+ Read More